Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | BMPR1B | O00238 | 14/20 | 0.34 |
| ▸ | BMPR1A | P36894 | 14/20 | 0.34 |
| ▸ | ACVRL1 | P37023 | 14/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 14/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 13/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21476004 | 0.87 | PTGS2 (0.37) | PTGS2BMPR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL21484165 | 0.81 | PTGS2 (0.37) | PTGS2BMPR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL21476022 | 0.78 | PTGS2 (0.35) | PTGS2BMPR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL22381370 | 0.78 | AOC2 (0.36) | PTGS2SCD5 | |
| SCHEMBL15807129 | 0.73 | PTGS2 (0.42) | PTGS2BMPR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL21476011 | 0.72 | AVPR1B (0.39) | PTGS2BMPR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL1106463 | 0.72 | PTGS2 (0.41) | PTGS2BMPR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL21475964 | 0.70 | HRH3 (0.50) | — | |
| SCHEMBL1106511 | 0.69 | HRH3 (0.41) | PTGS2BMPR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL27256766 | 0.68 | PTGS2 (0.38) | PTGS2BMPR1BBMPR1AACVRL1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759756-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| WO-2019200202-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | PTGS2 4366/4885BMPR1B 1808/4885BMPR1A 1773/4885 |
| US-10759756-B2 | Antagonists of human integrin α4β7 | ITGB7, ITGB4, ITGA4 | PTGS2 4438/4885BMPR1B 1979/4885BMPR1A 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.